期刊
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2020.00223
关键词
asthma; chronic obstructive pulmonary disease; fibroblast growth factor 2; immunomodulation therapeutics; airway structural cells
资金
- National Natural Science Foundation of China [81870019]
- Guangdong Provincial Natural Science Foundation [2018A030313554]
- National Key R&D Program of China [2018YFC0910601]
- National Medical Research Council, Singapore [NMRC/CIRG/1458/2016]
- Chinese Postdoctoral Science Foundation [2019M660211]
- Science and Technology Program of Guangzhou, China [201704020179]
- Ministry of Education academic research fund under the Tier 2 [MOE2015-T2-2]
- NUHS Bench-to-Bedside grant [NUHSRO/2014/078/STB/B2B FY14/15]
- European Allergy and Clinical Immunology (EAACI)
The fibroblast growth factor 2 (FGF2) is a potent mitogenic factor belonging to the FGF family. It plays a role in airway remodeling associated with chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). Recently, research interest has been raised in the immunomodulatory function of FGF2 in asthma and COPD, through its involvement in not only the regulation of inflammatory cells but also its participation as a mediator between immune cells and airway structural cells. Herein, this review provides the current knowledge on the biology of FGF2, its expression pattern in asthma and COPD patients, and its role as an immunomodulatory factor. The potential that FGF2 is involved in regulating inflammation indicates that FGF2 could be a therapeutic target for chronic inflammatory diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据